Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway (NCT07175376) | Clinical Trial Compass
RecruitingNot Applicable
Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway
United States32 participantsStarted 2026-03-16
Plain-language summary
The study purpose is to gain a better understanding of the needs of adults aged 65 and older while they are receiving chemotherapy by measuring their resilience and tailor care plans based on their individual needs.
Who can participate
Age range65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Patients with cancer:
* Ability to understand and willingness to sign an IRB-approved informed consent
* Age ≥ 65 years at the time of enrollment.
* Planned to initiate an outpatient chemotherapy regimen for cancer treatment (any type or stage), either as an initial therapy or as a new line of therapy, with curative or palliative intent.
* eFI pre-frail or frail status (available in EHR) within 30 days before enrollment.
* Ability to read and understand the English language
Providers:
* Treating medical oncologist of at least one patient participant who enrolled on to the study and completed baseline assessment.
Exclusion Criteria:
Patients:
* Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study per the enrolling investigator.
* Chemotherapy planned at a facility outside the Atrium Health system.
* Currently receiving chemotherapy
What they're measuring
1
Recruitment rate
Timeframe: Enrollment
2
Retention rate
Timeframe: At 12 weeks after initiation of standard of care chemotherapy